DBV Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

DBV Technologies şirketinin toplam hissedar öz sermayesi $54.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $93.1M ve $39.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$46.44m
Eşitlik	US$54.03m
Toplam yükümlülükler	US$39.02m
Toplam varlıklar	US$93.06m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DBV 'nin kısa vadeli varlıkları ( $68.8M ) kısa vadeli yükümlülüklerini ( $30.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: DBV şirketinin kısa vadeli varlıkları ( $68.8M ) uzun vadeli yükümlülüklerini ( $8.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DBV borçsuzdur.

Borcun Azaltılması: DBV şirketinin 5 yıl önce borç/öz sermaye oranı 1.7% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DBV şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 14.7 oranında tarihsel oranda büyümeye devam ederse DBV un bir yıldan az nakit akışı süresi vardır.

DBV Technologies Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe

Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

New major risk - Share price stability

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.22 loss in 1Q 2023)

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Insufficient new directors

DBV Technologies S.A., Annual General Meeting, May 16, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.24 loss in FY 2022)

New major risk - Financial position

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

Forecast to breakeven in 2026

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

New minor risk - Share price stability

DBV Technologies S.A. to Present New Data at ACAAI 2023

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.18 loss in 3Q 2022)

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.30 loss in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$1.24 loss per share (vs US$1.78 loss in FY 2021)

Forecast to breakeven in 2025

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.44 loss in 3Q 2021)

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Second quarter 2022 earnings released: US$0.35 loss per share (vs US$0.56 loss in 2Q 2021)

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.54 loss in 1Q 2021)

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022

DBV Technologies S.A. Provides Update on Investigational Viaskin Peanut

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$0.56 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.88 loss in 2Q 2020)

Independent Director has left the company

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.89 loss in 1Q 2020)

Revenue misses expectations

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies S.A. to Report First Half, 2021 Results on Aug 02, 2021

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

New 90-day high: €5.52

New 90-day high: €4.38

Hugh Sampson Decides to Step Down as Chief Scientific Officer of DBV Technologies, Effective December 1, 2020

New 90-day high: €4.15

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies S.A. Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

New 90-day low: €2.69

New 90-day low: €2.81

New 90-day low - €3.47

New 90-day low - €3.95

New 90-day low - €4.14

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço